BioSpace News Archive

Utilizing the power of artificial intelligence and natural language generation, Narrativa enables corporations to more effectively and efficiently save time and provide clarity on all data analytics for internal and external reporting

Imbio, a leading medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and Riverain Technologies™, a leader in clinical AI for lung nodules, announce a partnership to deliver a more complete lung health solution for clinicians, health systems, and radiology practices

Axonics ® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval

electroCore anticipates results of the company’s two clinical studies on non-invasive vagus nerve stimulation for acute treatment of stroke

EMulate Therapeutics Inc, a clinical-stage therapeutic device company, announced today a corporate update. Featured in a Healthcare Tech Outlook article, titled Ushering in a New Era in Non-Invasive Cancer Therapy, featured in Healthcare Tech Outlook.

Imugene enhances portfolio with novel CD19-expressing oncolytic virus from City of Hope, a comprehensive cancer center in Los Angeles, California, to be developed in combination with CD19-CAR T cell therapy

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced that Alex Howarth has joined Madrigal as Chief Financial Officer.

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the appointments of John A. Hohneker, M.D., Sigurd C. Kirk, and Peter T.C. Ho, M.D., Ph.D. to its Board of Directors. Mr. Kirk was also appointed to serve on the Audit Committee of the Board.

GeneThera is pleased to announce that it has incorporated a subsidiary in the United Kingdom. GeneThera Robotics Ltd, a majority owned subsidiary based in England, will be responsible for UK and International Operations.